Progenics Pharmaceuticals, Inc. Aktie

Aktier

2024-03-01	Perspective Therapeutics, Inc. (NYSEAM:CATX) har slutfört förvärvet av produktionsanläggningen för radiofarmaka i Somerset, New Jersey från Progenics Pharmaceuticals, Inc.	CI
2020-05-07	Progenics Pharmaceuticals, Inc., Q1 2020 Earnings Call, May 07, 2020
2019-12-23	Progenics Pharmaceuticals, Inc. - Special Call
2019-10-02	Lantheus Holdings, Inc., Progenics Pharmaceuticals, Inc. - M&A Call
2019-08-09	Progenics Pharmaceuticals, Inc., Q2 2019 Earnings Call, Aug 09, 2019
2019-05-09	Progenics Pharmaceuticals, Inc., Q1 2019 Earnings Call, May 09, 2019
2019-03-14	Progenics Pharmaceuticals, Inc., Q4 2018 Earnings Call, Mar 14, 2019
2018-11-13	Progenics Pharmaceuticals, Inc. Presents at 27th Annual Credit Suisse Healthcare Conference, Nov-13-2018 09:10 AM
2018-11-08	Progenics Pharmaceuticals, Inc., Q3 2018 Earnings Call, Nov 08, 2018
2018-10-05	Progenics Pharmaceuticals, Inc. - Special Call
2018-07-31	Progenics Pharmaceuticals, Inc. - Special Call
2018-05-09	Progenics Pharmaceuticals, Inc., Q1 2018 Earnings Call, May 09, 2018
2018-03-08	Progenics Pharmaceuticals, Inc., Q4 2017 Earnings Call, Mar 08, 2018

2024-03-01	Perspective Therapeutics, Inc. completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.
2024-01-09	Perspective Therapeutics, Inc. entered into an asset purchase agreement to acquire Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc. for $8 million.
2020-12-28	International Isotopes Inc. Terminates Manufacturing and Supply Agreement with Progenics Pharmaceuticals, Inc
2020-11-13	Lantheus Holdings, Inc., Progenics Pharmaceuticals, Inc., and Exini Diagnostics AB Announces U.S. Food and Drug Administration Clearance for Ai-Enabled Automated Bone Scan Index in Prostate Cancer on GE Healthcare’S Xeleris Platform
2020-06-22	PROGENICS PHARMACEUTICALS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)

Verkställande direktör	Titel	Ålder	Sedan
David Mims CEO	Verkställande Direktör	62	-

Datum	Insider	Typ	Huvudposition	Kvantitet	% av börsvärdet.
20-06-19	Heinz Christoph Mäusli	Försäljning av emittenten	Styrelseledamot	56 393	0,0651%
20-06-19	Karen Ferrante	Försäljning av emittenten	Styrelseledamot	170 000	0,1963%
20-06-19	Bryce V. Tenbarge	Försäljning av emittenten	Chef / ledande befattningshavare	389 864	0,4502%

Lägg till i en lista 0 vald För att använda denna funktion måste du vara en kund eller medlem Logga in Registrera dig	Förändring	Utveckling 5 d	Varia. 1 år	Föränd. 3 år	Kapi.($)
PROGENICS PHARMACEUTICALS, INC.	-.--%	+1,49 %	-	-	355 mn
WUXI APPTEC CO., LTD.	−2,11 %	−1,68 %	+44,52 %	+95,15 %	66,93 md
ARGENX SE	−0,23 %	−4,45 %	+32,50 %	+75,75 %	61,97 md
INSMED INCORPORATED	+1,67 %	+2,47 %	−11,32 %	+380,54 %	28,27 md
WUXI BIOLOGICS (CAYMAN) INC.	−1,05 %	−4,43 %	+28,84 %	+10,59 %	24,59 md
BIONTECH SE	+0,34 %	−6,78 %	−0,01 %	−16,35 %	24,3 md
GENMAB A/S	+0,43 %	−3,37 %	+16,22 %	−17,99 %	19,41 md
PHARMAESSENTIA CORPORATION	−3,03 %	−2,29 %	+181,72 %	+335,27 %	16,77 md
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	−1,94 %	−4,94 %	−8,15 %	+483,69 %	14,18 md
EXELIXIS, INC.	−2,28 %	−4,90 %	+43,35 %	+154,05 %	13,91 md
Genomsnitt	−0,82 %	−3,46 %	+36,41 %	+166,74 %	30,04 md
Viktad genomsnitt av Capi.	−0,84 %	−3,06 %	+34,15 %	+133,01 %